Reata Pharmaceuticals RETA

$ 172.36 0.0%

Quarterly report 2023-Q1
added 05-10-2023

Reata Pharmaceuticals Balance Sheet 2011-2024 | RETA

Annual Balance Sheet Reata Pharmaceuticals

	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	77.2 M	-454 M	-	-509 M	-259 M	-110 M	-84.7 M	-42 M	-87.8 M	-177 M	-	-
Long Term Debt	117 M	133 M	-	155 M	79.2 M	18.4 M	-	-	-	-	-	-
Long Term Debt Current	2.15 M	3.14 M	2.84 M	3.16 M	-	1.23 M	-	-	-	-	-	-
Total Non Current Liabilities	521 M	495 M	321 M	234 M	274 M	235 M	245 M	291 M	342 M	391 M	-	-
Total Current Liabilities	59 M	54 M	119 M	192 M	55.9 M	47.6 M	59.6 M	-	-	-	-	-
Total Liabilities	-	-	-	426 M	330 M	282 M	304 M	352 M	400 M	507 M	-	-
Deferred Revenue	-	1.65 M	4.69 M	4.7 M	31.3 M	28.2 M	46.6 M	49.7 M	49.6 M	51 M	-	-
Retained Earnings	-1.57 B	-1.26 B	-958 M	-710 M	-420 M	-337 M	-289 M	-283 M	-282 M	-282 M	-	-
Total Assets	514 M	735 M	858 M	682 M	345 M	135 M	89.1 M	79 M	126 M	229 M	-	-
Cash and Cash Equivalents	42.3 M	590 M	818 M	664 M	338 M	130 M	84.7 M	42 M	87.8 M	-	-	-
Book Value	514 M	735 M	858 M	257 M	15.2 M	-147 M	-215 M	-273 M	-274 M	-277 M	-	-
Total Shareholders Equity	-65.7 M	186 M	417 M	257 M	15.2 M	-147 M	-215 M	-273 M	-274 M	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Reata Pharmaceuticals

	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	115 M	117 M	135 M	134 M	136 M	133 M	57 K	962 K	1.73 M	-	-	-	156 M	155 M	155 M	155 M	155 M	79.2 M	79.2 M	78.6 M	79.2 M	18.4 M	18.4 M	18.4 M	18.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	530 M	521 M	528 M	517 M	508 M	495 M	355 M	343 M	331 M	321 M	321 M	321 M	321 M	234 M	234 M	234 M	234 M	274 M	274 M	274 M	274 M	235 M	235 M	235 M	235 M	245 M	245 M	245 M	245 M	291 M	291 M	291 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	755 K	1.65 M	2.56 M	3.09 M	3.89 M	4.69 M	4.69 M	4.69 M	4.69 M	4.7 M	4.7 M	4.7 M	4.7 M	31.3 M	31.3 M	31.3 M	28.8 M	28.2 M	30.6 M	36 M	41.3 M	46.6 M	46.6 M	46.6 M	46.6 M	49.7 M	49.7 M	49.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-1.68 B	-1.57 B	-1.48 B	-1.4 B	-1.33 B	-1.26 B	-1.17 B	-1.1 B	-1.03 B	-958 M	-958 M	-958 M	-958 M	-710 M	-710 M	-710 M	-710 M	-420 M	-420 M	-420 M	-420 M	-337 M	-337 M	-337 M	-337 M	-289 M	-289 M	-289 M	-289 M	-283 M	-283 M	-283 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	454 M	514 M	584 M	632 M	680 M	735 M	732 M	778 M	815 M	858 M	858 M	858 M	858 M	682 M	682 M	682 M	682 M	345 M	345 M	345 M	345 M	135 M	135 M	135 M	135 M	89.1 M	89.1 M	89.1 M	89.1 M	79 M	79 M	79 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	84.9 M	42.3 M	31.9 M	147 M	532 M	590 M	713 M	756 M	778 M	818 M	818 M	818 M	818 M	664 M	664 M	664 M	664 M	338 M	338 M	338 M	338 M	130 M	130 M	130 M	130 M	84.7 M	84.7 M	84.7 M	84.7 M	42 M	42 M	42 M	-	87.8 M	-	-	-	177 M	-	-	-	-	-	-	-	-	-	-	-
Book Value	454 M	514 M	584 M	632 M	680 M	735 M	732 M	778 M	815 M	858 M	858 M	858 M	858 M	682 M	682 M	682 M	682 M	345 M	345 M	345 M	345 M	135 M	135 M	135 M	135 M	89.1 M	89.1 M	89.1 M	89.1 M	79 M	79 M	79 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	-131 M	-65.7 M	4.52 M	68.6 M	128 M	186 M	256 M	314 M	369 M	417 M	417 M	417 M	417 M	257 M	257 M	257 M	257 M	15.2 M	15.2 M	15.2 M	15.2 M	-147 M	-147 M	-147 M	-147 M	-215 M	-215 M	-215 M	-215 M	-273 M	-273 M	-273 M	-	-274 M	-	-	-	-277 M	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency